FDA requires vision-loss warnings on GLP-1 weight-loss drugs
The FDA has ordered new warning labels for GLP-1 medications after a review found a higher incidence of a rare optic-nerve disorder among users.
The U.S. Food and Drug Administration has directed manufacturers of GLP-1 drugs, including Ozempic and Wegovy, to add warning labels about a small risk of permanent vision loss. The agency’s review of 126 clinical trials involving 134,253 participants identified a higher occurrence of non-arteritic anterior ischemic optic neuropathy (NAION) among patients taking these medications.
The meta-analysis estimated roughly six cases of NAION per 100,000 GLP-1 users over a year, compared with fewer than four cases in placebo or other glucose-lowering drug groups. Overall, GLP-1 users showed about a 68% higher rate of the condition, though the FDA noted that the data do not prove a causal relationship.
Risk factors for NAION—such as diabetes, high blood pressure and sleep apnea—are common among people prescribed GLP-1 therapies, complicating the assessment of whether the drugs themselves contribute to the increased risk. Of the approximately 78,000 patients examined, ten experienced vision loss, representing roughly 0.01% of the study population.
NAION is a rare optic-nerve disorder that can cause sudden, painless vision loss, typically in one eye upon waking, and currently has no proven treatment to reverse damage. The FDA’s action aims to ensure patients are informed of this potential risk while further research continues.